Dr. Jörg Reinhardt

Leverkusen, April 21, 2010 – Dr. Jörg Reinhardt has been appointed Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee effective August 15, 2010. The 54-year-old German national was latterly Chief Operating Officer of Novartis AG, Basel, Switzerland. “Dr. Reinhardt is an acknowledged expert with many years of experience in the health care industry,“ commented Werner Wenning, Chairman of the Board of Management of Bayer AG. “We are convinced of his ability to provide a decisive impetus to our global HealthCare business and further expand our strong competitive positions.“
Current HealthCare CEO Arthur J. Higgins will leave the company as planned on April 30, 2010 at his own request. “Over the past years, Arthur Higgins has made a decisive contribution to the restructuring and strengthening of Bayer HealthCare and has set new trends,” said Wenning. “We thank him for his great commitment and wish him well for the future.” Dr. Marijn Dekkers, member of the Bayer AG Board of Management and its designated Chairman, will additionally take over as head of Bayer HealthCare on a temporary basis as planned from May 1, 2010 until Dr. Reinhardt’s appointment takes effect.

Dr. Jörg Reinhardt, born on March 11, 1956 in Homburg in the German state of Saarland, studied pharmaceutical sciences at the University of Saarbrücken. After obtaining his doctorate in 1981, he started his career with Sandoz, a predecessor company of Novartis, in 1982, holding various managerial positions of increasing responsibility in research and development. He was appointed Head of Corporate Development in 1994. After the formation of Novartis in 1996, he served as Head of Preclinical Development and Project Management before being appointed Global Head of Development in 1999. In this capacity he was responsible for clinical, pharmaceutical, chemical and biotechnological development, drug safety testing and regulatory affairs. At the end of 2005 he was appointed CEO of the Vaccines & Diagnostics Division, San Francisco/Boston, United States. At the end of 2008, Reinhardt returned to Switzerland to become Chief Operating Officer (COO) of Novartis, a position he held until the end of January 2010. In this capacity Reinhardt was responsible for all four of the group’s divisions as well as for Human Resources, IT, Corporate Affairs and Communications. He was also a member of the company’s Executive Committee.

From 2000 until January 2010, Reinhardt also served as Chairman of the Board of Directors of the Genomics Institute of the Novartis Foundation in La Jolla, California. From 2001 through 2004 he was a member of the Supervisory Board of MorphoSys AG, Germany, which specializes in researching and developing monoclonal antibodies.